Author  
Place of duty  
Title   소세포성 폐암에 대한 Cispatin , Ifosfamide , Etoposide 복합화학요법의 효과 ( Combination Chemotherapy with Cisplatin , Ifosfamide , and Etoposide in Small Cell Lung Cancer )
Publicationinfo   1999 Jan; 031(04): 692-699.
Key_word   Small cell lung cancer, Cisplatin, Etoposide, Ifosfamide, Chemotherapy
Full-Text  
Abstract   Purpose: Although chemotherapy is considered as the mainstay of treatment for small cell lung cancer, long-term survival is not expected in the majority of patients. Until more effective drugs are developed, optimization of available chemotherapeutic regimens and the combination with radiotherapy will be required to improve the survival of small cell lung cancer patients. We conducted a phase II trial to evaluate the effect of a combination chemotherapy of cisplatin, ifosfamide, and etoposide. Materials and Methods: From January 1994 to December 1997, 34 untreated small cell lung cancer patients were enrolled in this study. The treatment schedule included etoposide 80 mg/m/day, ifosfamide 1.5 g/m'/day, cisplatin 20 mg/m/day iv continuous infusion on day 1-3. Cycles were repeated every 4 weeks. Results: The objective response rate was 58% [localized disease (LD), 100%; extensive disease (ED), 48%]. And complete remission rate was 19% (LD, 38%; ED, 13%). The median survival of all patients was 12 months (LD, 17 months; ED, 12 months). The median duration of response was 7 months. There was one treatment-related death. The hematologic toxicities were tolerable: Leukopenia greater than Grade III was 25%, and thrombocytopenia greater than Grade III was 6%. Nausea and vomiting were seen in most patients, but they were controllable. Conclusion: The combination chemotherapy with cisplatin, ifosfamide, and etoposide as a first line therapy seemed effective with tolerable toxicity in patients with small cell lung cancer.
저 자   최인근(In Keun Choi),김병수(Byung Soo Kim),심재정(Jae Jeong Shim),신상원(Sang Won Shin),김열흥(Yeul Hong Kim),강경호(Kyung Ho Kang),김광택(Kwang Taek Kim),김준석(Jun Suk Kim),최영호(Young Ho Choi)